Khawaja Husnain Haider Knihy

This book is a continuum of the first two books published in the STEM CELLS series entitled „Stem Cells: From Drug to Drug Discovery“ and „Stem Cells: From Hype to Real Hope“ which were published in 2017 and 2019, respectively. The scope of the book encompasses a wide range of topics with a latitude from adult stem cells to pluripotent stem cells in regenerative medicine either alone or as part of the combinatorial therapeutic intervention approach as „drug“ besides their application as tools (disease model) during drug development process. Written by a leading group of researchers, the book encompasses experimental to clinical aspects of stem/progenitors cells, their biology, and characteristics.

This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled "Stem Cells: from Drug to Drug Discovery" which was published in 2017.

Stem cell based therapy is a 21 st century approach of therapeutic intervention which epitomizes a shift from conventional symptomatic treatment strategy to addressing the root cause of the disease process. This is especially a hope for the patients suffering from diseases such as Alzheimer, diabetes, myocardial infarction and other diseases which have always been considered as incurable. Moreover, stem cells provide excellent in vitro disease models for drug development. This book is a compilation of the bench experience of experts from various research labs involved in the cutting edge area of research, describing the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development.